[Dawn of Cancer Clinical Sequencing in Chiba University Hospital]
Related Experiment Video
Updated: Feb 3, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
Masayuki Kano1, Hideaki Miyauchi, Kazuyuki Matsushita
1Dept. of Frontier Surgery, Graduate School of Medicine, Chiba University.
Abstract:
Genome medicine has been attractingmuch of attention in Japan. The combination of molecular targetingdrug s and somatic mutations has been developed for cancer treatment, which was introduced clinically with evidence by cancer type. Several cancer somatic mutations can be identified in a single test inexpensively using next-generation sequencing(NGS). Drug approval not based on organs but on cancer genome analysis has been practiced mainly in the United States, and is also being implemented in Japan. However, cancer treatment strategies using molecular targeting drugs and the associated diagnosis are limited in each type of cancer. Furthermore, the benefit of NGS, which is an improved and inexpensive technique, is still insignificant in Japan. However, the clinical biobank system was initiated in 2011 to prepare the era of cancer genome medicine in our department. The quality of biological samples was strictly controlled by the standardized sampling procedures, which can be used by the researchers accordingto their convenience. Furthermore, the cooperative research involvingcommercial corporations has been started.
Insights
Cancer genome medicine in Japan is advancing with molecular targeted drugs and next-generation sequencing (NGS). A clinical biobank system supports this progress, aiming for personalized cancer treatments.
Area of Science:
- Genomics and Precision Medicine
- Oncology
- Biotechnology
Background:
- Genome medicine, particularly in cancer treatment, is gaining significant attention in Japan.
- Molecular targeted drugs, guided by somatic mutations, are increasingly used in clinical practice.
- Next-generation sequencing (NGS) enables cost-effective identification of multiple cancer somatic mutations.
Purpose of the Study:
- To explore the current landscape and future potential of cancer genome medicine in Japan.
- To highlight the integration of molecular targeted therapies with genomic profiling.
- To discuss the establishment of a clinical biobank system to support future cancer research.
Main Methods:
- Analysis of clinical implementation of molecular targeted drugs based on cancer type.
- Evaluation of next-generation sequencing (NGS) for identifying cancer somatic mutations.
- Description of the establishment and quality control of a clinical biobank system.
Main Results:
- While molecular targeted therapies and NGS are advancing, their clinical impact in Japan is still developing.
- Drug approvals based on cancer genome analysis are being adopted in Japan, mirroring US practices.
- A robust clinical biobank system with standardized procedures was established in 2011.
Conclusions:
- Japan is preparing for the era of cancer genome medicine through initiatives like clinical biobanks.
- Cooperative research with commercial corporations is being initiated to advance the field.
- Despite current limitations, the infrastructure for personalized cancer treatment is being built.
Related Concept Videos
Hospitals-II
Nurses that work in...
Hospitals-I
Cis-regulatory Sequences
Sequences
Sanger Sequencing
Arithmetic Sequences

